Literature DB >> 18261593

Liver transplantation for Wilson's disease.

S Sevmis1, H Karakayali, I Aliosmanoglu, U Yilmaz, F Ozcay, A Torgay, G Arslan, M Haberal.   

Abstract

Wilson's disease is an inherited disorder of copper metabolism characterized by reduced biliary copper excretion, which results in copper accumulation in the tissues with liver injury and failure. Orthotopic liver transplantation (OLT) can be lifesaving for patients with Wilson's disease who present with fulminant liver failure and for patients' unresponsive to medical therapy. The aim of this study was to review our experience with OLT for patients with Wilson's disease. Between September 2001 and April 2007, 25 OLTs were performed in 24 patients (7 females and 17 males) with Wilson's disease of mean age 15.6 +/- 9.9 years (range, 5-51 years). Six patients underwent transplantation owing to coexistent fulminant hepatic failure and 18 with chronic advanced liver disease with (n = 8) or without (n = 10) associated neurologic manifestations. We performed 3 full-size, deceased-donor OLTs and 22 living-related donor OLTs. Eight patients had a family history of Wilson's disease. We detected a Kayser-Fleischer ring in 18 patients. All patients had a low serum ceruloplasmin level (mean, 27.8 mg/dL) and a high urinary copper excretion level (mean, 4119 mug/d) before OLT. Following successful OLT, there was a significant reduction in urinary copper excretion (median, 37.1 mug/d) in all patients. Mean follow-up was 21.7 +/- 19.8 months (range, 2-60 months). Retransplantation was required in 1 patient at 12 days after the first OLT owing to primary graft nonfunction. Five of the 24 patients died within 4 months of the surgery. The remaining 19 survivors (79%) have remained well, with normal liver function and no disease recurrence. In conclusion, OLT was a curative procedure for Wilson's disease among patients presenting with fulminant hepatic failure and others with end-stage hepatic insufficiency. After OLT, the serum ceruloplasmin level increased to the normal range, urinary copper excretion decreased, and neurologic manifestations improved.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18261593     DOI: 10.1016/j.transproceed.2007.11.007

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  6 in total

1.  Diagnosis and management of fulminant Wilson's disease: a single center's experience.

Authors:  Yi Tian; Guo-Zhong Gong; Xu Yang; Feng Peng
Journal:  World J Pediatr       Date:  2015-06-04       Impact factor: 2.764

2.  Brain MRI in the Decision for Liver Transplantation in Pediatric Neurological Wilson's Disease.

Authors:  Catarina Pinto; Maria João Malaquias; Helena Pessegueiro Miranda; Teresa Temudo; Ermelinda Silva; Cristina Ramos; Marina Magalhães
Journal:  Mov Disord Clin Pract       Date:  2022-09-08

Review 3.  Disorders of metal metabolism.

Authors:  Carlos R Ferreira; William A Gahl
Journal:  Transl Sci Rare Dis       Date:  2017-12-18

4.  Liver transplantation as a treatment for Wilson's disease with neurological presentation: a systematic literature review.

Authors:  Tomasz Litwin; Jan Bembenek; Agnieszka Antos; Adam Przybyłkowski; Marta Skowrońska; Iwona Kurkowska-Jastrzębska; Anna Członkowska
Journal:  Acta Neurol Belg       Date:  2022-01-26       Impact factor: 2.396

5.  Fourteen Years of Experience of Liver Transplantation for Wilson's Disease; a Report on 107 Cases from Shiraz, Iran.

Authors:  Kamran B Lankarani; Seyed Ali Malek-Hosseini; Saman Nikeghbalian; Mohsen Dehghani; Mohammad Pourhashemi; Kourosh Kazemi; Parisa Janghorban; Maryam Akbari; Sulmaz Ghahramani; Bijan Eghtesad; Maryam Moini; Abbas Rahmi Jaberi; Alireza Shamsaifar; Siavosh Gholami; Fatemeh Rahmanian; Bita Geramizadeh
Journal:  PLoS One       Date:  2016-12-08       Impact factor: 3.240

6.  Wilson disease in 71 patients followed for over two decades in a tertiary center in Saudi Arabia: a retrospective review.

Authors:  Mohammed Al Fadda; Mohammed Al Quaiz; Hamad Al Ashgar; Khalid Al Kahtani; Ahmed Helmy; Ali Al Benmousa; Maheeba Abdulla; Musthafa Peedikayil
Journal:  Ann Saudi Med       Date:  2012 Nov-Dec       Impact factor: 1.526

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.